---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-26-000053"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2026-07-28T11:02:34+00:00"
generated_at: "2026-07-28T11:05:27.734219+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte Q2 revenue $1.67B (+38% YoY); raises FY2026 guidance; acquires Vega Therapeutics for $1.25B

## Summary
- Total net sales $1.49B (+40% YoY); GAAP diluted EPS $2.81, Non-GAAP diluted EPS $3.09.
- Jakafi net sales $817M (+7%); Opzelura net sales $450M (incl. $246M one-time CMS benefit); ex-benefit $204M (+24%).
- Raises FY2026 total net sales guidance to $5.13-5.26B from $4.77-4.94B; Opzelura guidance to $1.05-1.1B.
- Completed acquisition of Vega Therapeutics for $1.25B upfront; adds latarcibart (Phase 3 VWD) to pipeline.
- Hematology/Oncology net sales $222M (+69%); Niktimvo, Monjuvi/Minjuvi, Zynyz drive growth.

## SEC filing metadata
- accession: 0000879169-26-000053
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2026-07-28T11:02:34+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/0000879169-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-20260728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-26-000053
- JSON: https://secwatch.observer/filing/0000879169-26-000053.json
- Plain text: https://secwatch.observer/filing/0000879169-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.